Luseogliflozin for the treatment of type 2 diabetes.

@article{Seino2014LuseogliflozinFT,
  title={Luseogliflozin for the treatment of type 2 diabetes.},
  author={Yutaka Seino},
  journal={Expert opinion on pharmacotherapy},
  year={2014},
  volume={15 18},
  pages={2741-9}
}
INTRODUCTION Sodium glucose cotransporter 2 (SGLT2) inhibitors are expected to provide adequate glycemic control, and be safe and well tolerated, for treating type 2 diabetes mellitus (T2DM). Luseogliflozin is a highly selective SGLT2 inhibitor that was recently approved for marketing and launched in Japan to treat T2DM. AREAS COVERED This review summarizes the published data regarding the mechanism of action, clinical efficacy, and safety of luseogliflozin for treating T2DM. Other potential… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS